David R. Gastfriend, MD, Psychiatry, Newton, MA

David R.GastfriendMD

Psychiatry Newton, MA

Addiction

Chief Architect, ASAM's CONTINUUM(TM); Scientific Advisor, Treatment Research Institute

Dr. Gastfriend is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gastfriend's full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalRESIDENCY
  • University of Pennsylvania
    University of PennsylvaniaINTERNSHIP
  • Sidney Kimmel Medical College
    Sidney Kimmel Medical CollegeMEDICAL_SCHOOL
  • Haverford CollegeOTHER_TRAINING

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2020 - 2021
  • MA State Medical License
    MA State Medical License 1982 - 2020
  • American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • Distinguished Fellow American Society of Addiction Medicine, 2016
  • ASAE Gold Award American Society of Association Executives, 2016
  • John P. McGovern, M.D. Award and Lecture for highly meritorious contributions to addiction and society in public policy, treatment, research or prevention. American Society of Addiction Medicine, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Attitudes and practices on the use of extended-release naltrexone in criminal justice settings  
    Festinger DS, Dugosh KL, Gastfriend DR, Sierka C, Drug Alc Dependence, 1/1/2017
  • Open-label study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence  
    Earley PH, Zummo J, Memisoglu A, Silverman BL, Gastfriend DR, J Addiction Medicine, 1/1/2017
  • Specialized community disease management to reduce substance use and hospital readmissions  
    Chambers JE, Brooks AC, Morrison MF, McKay JR, Gastfriend DR, Drug Alc Dependence, 1/1/2017
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Commentary on Nonpharmacologic Approaches to Substance Abuse Treatment
    Gastfriend, DR, Abstracts of Clinical Care Guidelines, Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL, 1/1/1998
  • Categorical vs. dimensional determination of alcoholic subtype and correlation with severity and personality
    Gastfriend DR, Lex BW, Waldman J, Mendelson J, Alcoholism: Clin Exp Research, 1/1/1990

Other

  • New Horizons for Treatment Strategies 
    Creed M, Crystal RG, Gastfriend DR, Tyndale RF, The New York Academy of Sciences. The Addicted Brain and New Treatment Frontiers: Sixth Annual Aspen
    www.nyas.org/addiction2016-eB
    1/1/2016
  • Treatment matching in substance use disorders (audiotape journal) 
    Gastfriend, DR, Practical Reviews in Psychiatry
    1/1/1996
  • Diagnosis and treatment matching in alcoholism (audiotape journal) 
    Gastfriend, DR, Practical Reviews in Psychiatry
    1/1/1989
  • Join now to see all

Press Mentions

  • Dr. David R. Gastfriend
    Dr. David R. Gastfriend
  • ASAM’s Assessment Software CONTINUUM™ to Be Used in Significant Clinical Trial
    ASAM’s Assessment Software CONTINUUM™ to Be Used in Significant Clinical Trial
  • ANNOUNCEMENT: Intent Solutions Announces New Advisory Board Member-- David Gastfriend
    ANNOUNCEMENT: Intent Solutions Announces New Advisory Board Member-- David GastfriendJanuary 17, 2017
  • Join now to see all

Grant Support

  • A Simple Large Trial of Patient‐Centered Care for Opioid Use Disorders in Federally Qualified Healthcare CentersPCORI - The Patient-Centered Outcomes Research Institute2017–2022
  • Improving Drug Abuse Treatment Planning CriteriaNational Institute On Drug Abuse2000–2004
  • Core--ClinicalNational Institute On Drug Abuse1997–2002
  • Validity Of The ASAM Criteria For Drug Abuse TreatmentNational Institute On Drug Abuse1994–2000

Professional Memberships

Industry Relationships

  • Consultant, IBM Watson - Truven Health AnalyticsProvide health outcomes research and policy guidance and technical assistance to IBM Watson research & evaluation staff and state Medicaid leadership, on behalf of U.S. Centers for Medicare & Medicaid Services (CMS)2016 - Present
  • Consultant, Rand Corp.Provide scientific expertise for algorithm mapping in clinical decision support and analysis.2016 - Present
  • Consultant, BioCorRx, Inc.2016 - Present
  • Consultant, Indivior, Inc.2016 - Present
  • Scientific Advisory Board Member, Recovery Corporation of America, Inc.2016 - 2017
  • Consultant, Purdue Pharma2016 - 2016
  • Consultant, Kaleo, Inc.2016 - 2016
  • Vice President, Alkermes, Inc.Provided guidance and oversight for the development of monthly injectable naltrexone, addressing basic, clinical RCT, effectiveness, health economic, and criminal justice research for this new formulation, which achieved FDA-approval in the treatment of both alcohol and opioid dependence.Disclosure: Consultant; shareholder2005 - 2013